FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889899146> ?p ?o ?g. }

• W2889899146 endingPage "91" @default.
• W2889899146 startingPage "73" @default.
• W2889899146 abstract "Background & AimsOropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance. To facilitate cancer therapy in personalized medicine, three-dimensional (3D) organoids may be useful for functional characterization of cancer cells ex vivo. We investigated the feasibility and the utility of patient-derived 3D organoids of esophageal and oropharyngeal squamous cell carcinomas.MethodsWe generated 3D organoids from paired biopsies representing tumors and adjacent normal mucosa from therapy-naïve patients and cell lines. We evaluated growth and structures of 3D organoids treated with 5-fluorouracil ex vivo.ResultsTumor-derived 3D organoids were grown successfully from 15 out of 21 patients (71.4%) and passaged with recapitulation of the histopathology of the original tumors. Successful formation of tumor-derived 3D organoids was associated significantly with poor response to presurgical neoadjuvant chemotherapy or chemoradiation therapy in informative patients (P = 0.0357, progressive and stable diseases, n = 10 vs. partial response, n = 6). The 3D organoid formation capability and 5-fluorouracil resistance were accounted for by cancer cells with high CD44 expression and autophagy, respectively. Such cancer cells were found to be enriched in patient-derived 3D organoids surviving 5-fluorouracil treatment.ConclusionsThe single cell-based 3D organoid system may serve as a highly efficient platform to explore cancer therapeutics and therapy resistance mechanisms in conjunction with morphological and functional assays with implications for translation in personalized medicine. Oropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance. To facilitate cancer therapy in personalized medicine, three-dimensional (3D) organoids may be useful for functional characterization of cancer cells ex vivo. We investigated the feasibility and the utility of patient-derived 3D organoids of esophageal and oropharyngeal squamous cell carcinomas. We generated 3D organoids from paired biopsies representing tumors and adjacent normal mucosa from therapy-naïve patients and cell lines. We evaluated growth and structures of 3D organoids treated with 5-fluorouracil ex vivo. Tumor-derived 3D organoids were grown successfully from 15 out of 21 patients (71.4%) and passaged with recapitulation of the histopathology of the original tumors. Successful formation of tumor-derived 3D organoids was associated significantly with poor response to presurgical neoadjuvant chemotherapy or chemoradiation therapy in informative patients (P = 0.0357, progressive and stable diseases, n = 10 vs. partial response, n = 6). The 3D organoid formation capability and 5-fluorouracil resistance were accounted for by cancer cells with high CD44 expression and autophagy, respectively. Such cancer cells were found to be enriched in patient-derived 3D organoids surviving 5-fluorouracil treatment. The single cell-based 3D organoid system may serve as a highly efficient platform to explore cancer therapeutics and therapy resistance mechanisms in conjunction with morphological and functional assays with implications for translation in personalized medicine." @default.
• W2889899146 created "2018-09-27" @default.
• W2889899146 creator A5000240113 @default.
• W2889899146 creator A5009711450 @default.
• W2889899146 creator A5010792621 @default.
• W2889899146 creator A5012701649 @default.
• W2889899146 creator A5020643034 @default.
• W2889899146 creator A5022854492 @default.
• W2889899146 creator A5023539776 @default.
• W2889899146 creator A5025465098 @default.
• W2889899146 creator A5028284770 @default.
• W2889899146 creator A5030182456 @default.
• W2889899146 creator A5033827229 @default.
• W2889899146 creator A5035025572 @default.
• W2889899146 creator A5046798526 @default.
• W2889899146 creator A5047261124 @default.
• W2889899146 creator A5047742804 @default.
• W2889899146 creator A5049069416 @default.
• W2889899146 creator A5049240982 @default.
• W2889899146 creator A5052023689 @default.
• W2889899146 creator A5052486855 @default.
• W2889899146 creator A5054395736 @default.
• W2889899146 creator A5063331240 @default.
• W2889899146 creator A5063991205 @default.
• W2889899146 creator A5067463702 @default.
• W2889899146 creator A5067647817 @default.
• W2889899146 creator A5070591384 @default.
• W2889899146 creator A5075639062 @default.
• W2889899146 creator A5077168668 @default.
• W2889899146 creator A5079706186 @default.
• W2889899146 creator A5081012989 @default.
• W2889899146 creator A5089057498 @default.
• W2889899146 creator A5090388223 @default.
• W2889899146 date "2019-01-01" @default.
• W2889899146 modified "2023-10-17" @default.
• W2889899146 title "Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells" @default.
• W2889899146 cites W1587752510 @default.
• W2889899146 cites W1606493563 @default.
• W2889899146 cites W1634699770 @default.
• W2889899146 cites W1741548448 @default.
• W2889899146 cites W1922694287 @default.
• W2889899146 cites W1963891946 @default.
• W2889899146 cites W1985213644 @default.
• W2889899146 cites W1988075836 @default.
• W2889899146 cites W1988313753 @default.
• W2889899146 cites W1994830230 @default.
• W2889899146 cites W1997114875 @default.
• W2889899146 cites W2002107497 @default.
• W2889899146 cites W2002513358 @default.
• W2889899146 cites W2010402293 @default.
• W2889899146 cites W2010916968 @default.
• W2889899146 cites W2019607817 @default.
• W2889899146 cites W2021169921 @default.
• W2889899146 cites W2024876545 @default.
• W2889899146 cites W2028593825 @default.
• W2889899146 cites W2028787381 @default.
• W2889899146 cites W2030781779 @default.
• W2889899146 cites W2036919653 @default.
• W2889899146 cites W2044928246 @default.
• W2889899146 cites W2059586354 @default.
• W2889899146 cites W2069452349 @default.
• W2889899146 cites W2069839886 @default.
• W2889899146 cites W2072212990 @default.
• W2889899146 cites W2079351077 @default.
• W2889899146 cites W2084606377 @default.
• W2889899146 cites W2103596198 @default.
• W2889899146 cites W2165254414 @default.
• W2889899146 cites W2293741465 @default.
• W2889899146 cites W2340065918 @default.
• W2889899146 cites W2346530374 @default.
• W2889899146 cites W2500815028 @default.
• W2889899146 cites W2523976396 @default.
• W2889899146 cites W2607389896 @default.
• W2889899146 cites W2611637086 @default.
• W2889899146 cites W2768561639 @default.
• W2889899146 cites W2782431872 @default.
• W2889899146 cites W2794100731 @default.
• W2889899146 cites W3213876936 @default.
• W2889899146 cites W4236032391 @default.
• W2889899146 cites W4249441028 @default.
• W2889899146 cites W4249692127 @default.
• W2889899146 doi "https://doi.org/10.1016/j.jcmgh.2018.09.003" @default.
• W2889899146 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6260338" @default.
• W2889899146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30510992" @default.
• W2889899146 hasPublicationYear "2019" @default.
• W2889899146 type Work @default.
• W2889899146 sameAs 2889899146 @default.
• W2889899146 citedByCount "93" @default.
• W2889899146 countsByYear W28898991462019 @default.
• W2889899146 countsByYear W28898991462020 @default.
• W2889899146 countsByYear W28898991462021 @default.
• W2889899146 countsByYear W28898991462022 @default.
• W2889899146 countsByYear W28898991462023 @default.
• W2889899146 crossrefType "journal-article" @default.
• W2889899146 hasAuthorship W2889899146A5000240113 @default.
• W2889899146 hasAuthorship W2889899146A5009711450 @default.
• W2889899146 hasAuthorship W2889899146A5010792621 @default.
• W2889899146 hasAuthorship W2889899146A5012701649 @default.

• next